Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 5/20 | 0.68 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14307356 | 0.91 | CYP3A4 (0.66) | MTNR1BGRIN2CCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5097146 | 0.90 | MTNR1B (0.70) | MTNR1BCYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL5103507 | 0.89 | GRIN2C (0.60) | MTNR1BGRIN2CCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5097155 | 0.87 | TP53 (0.66) | MTNR1BCYP3A4CYP2D6CYP2C19TP53 | |
| SCHEMBL5096743 | 0.87 | CYP3A4 (0.67) | MTNR1BGRIN2CCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5103362 | 0.86 | CYP3A4 (0.68) | MTNR1BGRIN2CCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5103450 | 0.86 | CYP3A4 (0.60) | MTNR1BCYP3A4CYP2D6CYP2C19TP53 | |
| SCHEMBL5096710 | 0.85 | CYP3A4 (0.64) | MTNR1BCYP3A4CYP2D6CYP2C19HCRTR1 | |
| SCHEMBL3541010 | 0.85 | CYP3A4 (0.64) | MTNR1BGRIN2CCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5090978 | 0.85 | CYP3A4 (0.64) | MTNR1BGRIN2CCYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033007-A1 | Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy | MILLER DUANE D | 2008-02-07 | — | — | US | disclosed |
| US-20080033007-A1 | Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy | MILLER DUANE D | 2008-02-07 | — | — | US | disclosed |
| US-20080033007-A1 | Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy | MILLER DUANE D | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033007-A1 | Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy | BAD, TP53, MCL1 | MTNR1B 1805/4885GRIN2C 520/4885CYP3A4 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.